Novo Nordisk Faces Critical Market Test with Q4 Results
02.02.2026 - 05:07:04
All eyes are on Danish pharmaceutical giant Novo Nordisk this week as it prepares to release its fourth-quarter 2025 financial results. The report, due Wednesday, arrives at a pivotal moment marked by intensifying competition in the lucrative GLP-1 drug market and the recent U.S. launch of a key new product.
The company will publish its Q4 2025 figures on February 4, 2026, prior to the opening of the Copenhagen market. A conference call and live webcast for investors will follow at 13:00 CET.
Market consensus, as compiled by Zacks, anticipates quarterly revenue of $11.96 billion and earnings per share (EPS) of $0.89. A year-over-year decline in the Read more...
@ boerse-global.de | DK0062498333 NOVO
